News and Announcements
YPB Signs Three-Year, Million Dollar Contract with Leading Pharma Company
- Published September 12, 2016 2:43PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
9th September 2016, ASX Announcement
- YPB to provide Brand Protection to Combiphar using the YPB CONNECT platform – expected to be implemented initially across tens of millions of products annually
- Expected revenue of approx. A$1m over the term of the three-year agreement
- Combiphar is a leading supplier of prescription and over-the-counter pharmaceuticals with around 170 product lines
Brand Protection and Customer Engagement solutions company YPB Group Limited (ASX: YPB) has signed a three-year agreement with leading Indonesian pharmaceutical and wellness company Combiphar for the supply of Brand Protection solutions in Asia.
YPB expects the three-year agreement to generate revenues of approximately A$1 million, with YPB technology to be applied to tens of millions of Combiphar products per annum over three of its 170 product lines.
To view the full article, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
